阿托伐他汀80毫克与瑞舒伐他汀40毫克对急性心肌梗死患者血清内脂素、chemerin和半乳糖凝集素-3水平的比较影响。
Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction.
作者信息
Tunçez Abdullah, Altunkeser Bülent Behlül, Öztürk Bahadır, Ateş Muhammed Salih, Tezcan Hüseyin, Aydoğan Canan, Kırık Emre Can, Yalçın Ulvi, Aygül Nazif, Demir Kenan, Akyürek Fikret
机构信息
Department of Cardiology, Faculty of Medicine, Selçuk University; Konya-Turkey.
Department of Biochemistry, Faculty of Medicine, Selçuk University; Konya-Turkey.
出版信息
Anatol J Cardiol. 2019 Nov;22(5):240-249. doi: 10.14744/AnatolJCardiol.2019.64249.
OBJECTIVE
Endocan, chemerin, and galectin-3 are discrete biomarkers associated with cardiovascular diseases and acting through different pathophysiological pathways. The aim of this study is to investigate and compare the effects of high doses of atorvastatin and rosuvastatin on serum endocan, chemerin, and galectin-3 levels in patients with acute myocardial infarction (AMI).
METHODS
Sixty-three patients with AMI were randomized to receive atorvastatin (80 mg/day) or rosuvastatin (40 mg/day) after percutaneous revascularization. Serum levels of endocan, chemerin, and galectin-3 were evaluated at baseline and after 4-week therapy.
RESULTS
Endocan levels were not decreased statistically significantly with atorvastatin 80 mg, but rosuvastatin 40 mg markedly decreased the levels of endocan according to baseline [from 110.27 (86.03-143.69) pg/mL to 99.22 (78.30-122.87) pg/mL with atorvastatin 80 mg and from 110.73 (77.28-165.22) pg/mL to 93.40 (70.48-115.13) pg/mL with rosuvastatin 40 mg, p=0.242 for atorvastatin 80 mg and p=0.014 for rosuvastatin 40 mg]. Chemerin levels significantly decreased in both groups according to baseline [from 264.90 (196.00-525.95) ng/mL to 135.00 (105.95-225.65) ng/mL with atorvastatin 80 mg and from 309.95 (168.87-701.27) ng/mL to 121.25 (86.60-212.65) ng/mL with rosuvastatin 40 mg, p<0.001, respectively, for both groups]. Galectin-3 levels did not change markedly with atorvastatin 80 mg, but they decreased with rosuvastatin 40 mg [from 17.00 (13.10-22.25) ng/mL to 19.30 (15.25-23.45) ng/mL with atorvastatin 80 mg, p=0.721, and from 18.25 (12.82-23.82) ng/mL to 16.60 (10.60-20.15) ng/mL with rosuvastatin 40 mg, p=0.074]. There were no significant between-group differences in terms of absolute and percentage changes of endocan, chemerin, and galectin-3 at 4 weeks.
CONCLUSION
We reported that both statins similarly decreased the endocan levels, whereas rosuvastatin seems to have more prominent effects on the reduction of the chemerin and galectin-3 levels in patients with AMI.
目的
内脂素、chemerin和半乳糖凝集素-3是与心血管疾病相关的不同生物标志物，通过不同的病理生理途径发挥作用。本研究旨在调查和比较大剂量阿托伐他汀和瑞舒伐他汀对急性心肌梗死（AMI）患者血清内脂素、chemerin和半乳糖凝集素-3水平的影响。
方法
63例AMI患者在经皮血管重建术后随机接受阿托伐他汀（80mg/天）或瑞舒伐他汀（40mg/天）治疗。在基线和4周治疗后评估血清内脂素、chemerin和半乳糖凝集素-3水平。
结果
80mg阿托伐他汀治疗后内脂素水平无统计学显著降低，但40mg瑞舒伐他汀根据基线显著降低了内脂素水平[80mg阿托伐他汀治疗后从110.27（86.03 - 143.69）pg/mL降至99.22（78.30 - 122.87）pg/mL，40mg瑞舒伐他汀治疗后从110.73（77.28 - 165.22）pg/mL降至93.40（70.48 - 115.13）pg/mL，80mg阿托伐他汀治疗时p = 0.242，40mg瑞舒伐他汀治疗时p = 0.014]。两组chemerin水平根据基线均显著降低[80mg阿托伐他汀治疗后从264.90（196.00 - 525.95）ng/mL降至135.00（105.95 - 225.65）ng/mL，40mg瑞舒伐他汀治疗后从309.95（168.87 - 701.27）ng/mL降至121.25（86.60 - 212.65）ng/mL，两组p均<0.001]。80mg阿托伐他汀治疗后半乳糖凝集素-3水平无明显变化，但40mg瑞舒伐他汀治疗后降低[80mg阿托伐他汀治疗后从17.00（13.10 - 22.25）ng/mL升至19.30（15.25 - 23.45）ng/mL，p = 0.721，40mg瑞舒伐他汀治疗后从18.25（12.82 - 23.82）ng/mL降至16.60（10.60 - 20.15）ng/mL，p = 0.074]。4周时内脂素、chemerin和半乳糖凝集素-3的绝对变化和百分比变化在组间无显著差异。
结论
我们报告两种他汀类药物同样降低了内脂素水平，而瑞舒伐他汀似乎对降低AMI患者的chemerin和半乳糖凝集素-3水平有更显著的作用。
Zotero 插件